Earnings Release • Nov 4, 2015
Earnings Release
Open in ViewerOpens in native device viewer
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 2.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,418 dialysis clinics, Fresenius Medical Care provides dialysis treatment for more than 294,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding in the range of additional medical services in the field of care coordination.
| Net revenue | \$ 16,738 M |
+6%/+11%cc |
|---|---|---|
| Operating income (EBIT) | \$ 2,327 M |
+3% |
| Operating income (EBIT) excluding special items1 | \$ 2,388 M |
+5% |
| Net income2 | \$ 1,029 M |
-2% |
| Net income excluding special items1,2 | 1,082 M | +2% |
| Basic earnings per share | \$ 3.38 |
-2% |
| Net cash provided by operating activities | \$ 1,960 M |
|
| Free cash flow | \$ 1,025 M |
|
| Free cash flow after investing activities | \$ 959 M |
|
| Employees | 104,033 | +4% |
| Patients | Treatments (in M) |
Clinics | |
|---|---|---|---|
| North America | 182,852 | 27.7 | 2,210 |
| EMEA | 54,857 | 8.2 | 659 |
| Asia-Pacific | 26,472 | 3.8 | 320 |
Latin America 30,200 4.9 229
Our strategy in the coming years will pursue the
| Our strategy in the coming years will pursue the following four strategic objectives: |
Growth in revenue | ~7-10% |
|---|---|---|
| Growing continuously and expanding our global presence |
Net income2 | ~15-20% |
| Tapping into new business areas |
Leverage ratio (Debt/EBITDA) | <3.0 |
| Enhancing products and treatments |
Capital expenditures | \$1.0 - \$1.1 BN |
| Expanding operational excellence and flexibility |
Acquisitions | ~\$750 M |
1 Excluding special items: divestiture of dialysis business in Venezuela, sale of the European marketing rights to Vifor and settlement costs for an agreement principle for the Granuflo® case in 2015 as well as closing of manufacturing plants in 2014. 2
attributable to shareholders of Fresenius Medical Care AG & Co. KGaA 3 Subject to approval by the Annual General Meeting on May 12, 2016.
September 30, 1996: Foundation of the company October 1, 1996: First listing of the shares on the Frankfurt Stock Exchange October 2, 1996: First listing of the shares on the New York Stock Exchange As of September 20, 1999: Inclusion in the DAX (Deutscher Aktienindex)
| Report on 1st quarter 2016: | May 3, 2016 | Fresenius Medical Care AG & Co. KGaA |
|---|---|---|
| Annual General Meeting 2016: | May 12, 2016 | Investor Relations & Corporate Communications |
| Dividend payment6 : |
May 13, 2016 | Else-Kröner-Str. 1, 61352 Bad Homburg |
| nd quarter 2016: Report on 2 |
August 2, 2016 | Email: [email protected] |
| Report on 3rd quarter 2016: | October 27, 2016 | Oliver Maier |
4as of February 19, 2016.
5Effective April 1, 2016 Roberto Fusté will be succeeded by Harry De Wit. 6Subject to approval by the Annual General Meeting on May 12, 2016.
| Ticker Symbols: | |
|---|---|
| Frankfurt Stock Exchange | FME |
| New York Stock Exchange (NYSE) | FMS |
| Reuters: XETRA / ADR NYSE: | FMEG.DE/FMS.N |
| Bloomberg: XETRA / ADR NYSE: | FME GY / FMS US |
| Security Identification numbers: | |
| WKN | 578 580 |
| ISIN | DE 0005785802 |
| CUSIP No. (NYSE) | 358029106 |
| Number of shares outstanding | 306,314,071 |
|---|---|
| Fresenius SE & Co. KGaA | 30.91% |
| BlackRock4 | >5% |
| Free float | ~64% |
| Market capitalization | \$22.8 M |
| Standard & Poor's | BBB- / stable outlook |
|---|---|
| Moody's | Ba1 / stable outlook |
| Fitch | BB+ / stable outlook |
Senior Vice President & Head of IR Please note that these dates might be subject to changes. P: +49(0)6172-609-2525 F: +49(0)6172-609-2301
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.